AB
TEVA icon

AT Bancorp’s Teva Pharmaceuticals TEVA Stock Holding History

AT Bancorp’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-18,727
Closed -$861K – 265
2016
Q3 		$861K Buy
+18,727
New +$977K 0.12% 164
2014
Q3 		– Sell
-32,884
Closed -$1.72M – 209
2014
Q2 		$1.72M Buy
+32,884
New +$1.68M 0.52% 71

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Barrow, Hanley, Mewhinney & Strauss
Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Nordea Investment Management
Nordea Investment Management Stockholm, Sweden $107B AUM 24.58% 1-Year Est. Return

AT Bancorp's TEVA Position: Q4 2016 in Review

AT Bancorp sold out of Teva Pharmaceuticals (TEVA) in Q4 2016, closing a stake of 18,727 shares — an estimated $861K sold.

AT Bancorp first reported a position in TEVA in Q2 2014 and held it in 2 quarters. The position peaked at $1.72M in Q2 2014. 737 funds tracked by Wall St. Rank hold TEVA as of Q4 2016.

  • AT Bancorp reported no remaining Teva Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • AT Bancorp sold 18,727 Teva Pharmaceuticals shares in Q4 2016, an estimated $861K.
  • AT Bancorp first reported a position in Teva Pharmaceuticals in Q2 2014 and held it in 2 quarters.
  • AT Bancorp's Teva Pharmaceuticals position peaked at $1.72M in Q2 2014.
  • 737 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2016.

Based on AT Bancorp's 13F filing for Q4 2016, filed 8 Feb 2017.